A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation

Authors
Category Primary study
JournalCancer research
Year 2022
This article has no abstract
Epistemonikos ID: 912a9e8f8ba52c3966ed9e8ae8c5977b0cde93c2
First added on: Dec 20, 2022